ArticleScience translational medicine2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review.Journal of translational medicine · 2025Pooled it
- Compensatory pathways in tryptophan metabolism and immune regulation following IDO inhibition.Molecular biology reports · 2026Review
- Review
- Multi-omics identification of SPON1-related risk model for predicting prognosis and drug response in ovarian cancer.Functional & integrative genomics · 2026Article
- Branching architecture of tryptophan metabolism determines therapeutic vulnerability in acute myeloid leukemia.Cell death & disease · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker-Guided Therapeutic Matching.Journal of cellular physiology · 2026Review
- Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation.Biomarker research · 2026Review
- Unmasking FCGR2B as a high-grade serous ovarian cancer specific marker of immune suppression and tumor progression through multi-omics mining.Translational oncology · 2026Article
- IDO family: the metabolic crossroads connecting immunity, nerves and tumors.Journal of translational medicine · 2026Review
- Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming.Molecular cancer · 2026Review
- IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Digital immune twins and ai-integrated multi-omic biomarkers: Redefining personalized immunotherapy in non-small cell lung cancer.Iranian journal of basic medical sciences · 2026Review
- PRMT3 in cancer: arginine methylation as a driver of tumor metabolism, immune evasion, and therapeutic resistance.Frontiers in immunology · 2026Review
- Bacterial tryptophan metabolites in cancer and atherosclerosis: insights for a role in immune checkpoint inhibition.Essays in biochemistry · 2025Review
- AR to GR switch modulates differential TDO2-Kyn-AhR signalling to promote the survival and recurrence of treatment-induced dormant cells in prostate cancer.Cell discovery · 2025Article
- Tryptophan metabolism: From physiological functions to key roles and therapeutic targets in cancer (Review).Oncology reports · 2025Review
- Evaluation of the Expression of IDO and PTEN in Human Kidney Cancer.Current issues in molecular biology · 2025Article
- Dendritic cell maturation in cancer.Nature reviews. Cancer · 2025Review
- Targeting the Kynurenine Pathway: A Novel Approach in Tumor Therapy.Expert reviews in molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 8 institutions in 1 country.
Kunle OdunsiUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.ORCID 0000-0002-4444-7651
Feng QianUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Amit A LugadeCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Han YuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Melissa A GellerDepartment of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0003-4591-620X
Steven P FlingCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-6263-0153
Judith C KaiserCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Andreanne M LacroixCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Leonard D'AmicoCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-1143-7297
Nirasha RamchurrenCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-6613-9342
Chihiro MorishimaCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Mary L DisisCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lucas DennisNanoString Technologies Inc., Seattle, WA, USA.ORCID 0000-0002-5299-8066
Patrick DanaherNanoString Technologies Inc., Seattle, WA, USA.ORCID 0000-0002-2844-5883
Sarah WarrenNanoString Technologies Inc., Seattle, WA, USA.ORCID 0000-0001-9465-8636
Van Anh NguyenDepartment of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.ORCID 0000-0003-1996-9340
Sudharshan RaviDepartment of Chemical and Biological Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.ORCID 0000-0001-6059-5403
Takemasa TsujiUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.ORCID 0000-0001-7563-2211
Spencer RosarioDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-2626-9257
Wenjuan ZhaDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-2477-2625
Alan HutsonDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Shashikant LeleDepartment of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-6207-8159
Emese ZsirosCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0003-0142-7375
A J Robert McGrayCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-7145-8444
Jessie ChielloCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0003-1978-1719
Richard KoyaUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.ORCID 0000-0002-7987-7811
Thinle ChodonUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
Carl D MorrisonDepartment of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0001-7514-3098
Vasanta PutluriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-7943-2209
Nagireddy PutluriDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0003-4488-7400
Donald E MagerDepartment of Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.ORCID 0000-0002-4848-0440
Rudiyanto GunawanDepartment of Chemical and Biological Engineering, University at Buffalo, State University of New York, Buffalo, NY, USA.ORCID 0000-0002-6480-7976
Martin A CheeverCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-6892-4141
Sebastiano BattagliaCenter for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-0809-8925
Junko MatsuzakiUniversity of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.ORCID 0000-0002-2555-1234
Roswell Park Comprehensive Cancer Center · USFred Hutch Cancer Center · USNanostring Technologies (United States) · USUniversity at Buffalo, State University of New York · USBaylor College of Medicine · USAngioDynamics (United States) · USUniversity of Minnesota · USUniversity of Washington · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MVIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MCancer Immunotherapy Trials Network Central Operations and Statistical CenterUM1CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DAVIDSON, NANCY ELLEN · 2017 to 2022
$20.7MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6MCancer Immunotherapy Trials Network Central Operations and Statistical CenterU01CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHEEVER, MARTIN ALEXANDER · 2010 to 2017
$16.8MImmuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HUTSON, ALAN DAVID, LIU, SONG · 2018 to 2024
$8.9MYAP1 and RB1 cooperate to regulate lung cancer lineage plasticity and therapeutic resistanceU24CA274159 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI DAVID W. GOODRICH, Alan David Hutson · 2022 to 2026
$8.5MCirculating Biomarkers and Imaging for Early Detection of Pancreatic CancerU01CA214263 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EUGENE J KOAY, Subrata Sen · 2018 to 2026
$7.2MU01 Proposal Transfer - 2021U01CA233085 · NCI · UNIVERSITY OF CHICAGO · PI GAMBOTTO, ANDREA, KOZBOR, DANUTA B · 2019 to 2019
$4.1MIdentify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of SmokersR01CA216426 · NCI · BAYLOR COLLEGE OF MEDICINE · PI EL-ZEIN, RANDA A, PUTLURI, NAGIREDDY · 2018 to 2022
$2.0MNCI NIH HHS P30 CA014599NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA216426NCI NIH HHS R01 CA220297NCI NIH HHS U01 CA154967NCI NIH HHS U01 CA214263NCI NIH HHS U01 CA233085NCI NIH HHS U24 CA232979NCI NIH HHS U24 CA274159NCI NIH HHS UM1 CA154967
Abstract
To uncover underlying mechanisms associated with failure of indoleamine 2,3-dioxygenase 1 (IDO1) blockade in clinical trials, we conducted a pilot, window-of-opportunity clinical study in 17 patients with newly diagnosed advanced high-grade serous ovarian cancer before their standard tumor debulking surgery. Patients were treated with the IDO1 inhibitor epacadostat, and immunologic, transcriptomic, and metabolomic characterization of the tumor microenvironment was undertaken in baseline and posttreatment tumor biopsies. IDO1 inhibition resulted in efficient blockade of the kynurenine pathway of tryptophan degradation and was accompanied by a metabolic adaptation that shunted tryptophan catabolism toward the serotonin pathway. This resulted in elevated nicotinamide adenine dinucleotide (NAD
Indexed as
Indoleamine-Pyrrole 2,3,-DioxygenaseOvarian NeoplasmsAnimalsFemaleHumansLymphocyte ActivationMiceNADTryptophanTumor MicroenvironmentIndoleamine-Pyrrole 2,3,-DioxygenaseNADTryptophan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.